Bellast Soft L
Next-generation hyaluronic acid dermal filler with 98.7% cross-linking efficiency and <0.05% BDDE residue
Advanced Dual Cross-linking Technology
Bellast Soft L utilizes patented SMART Cross-linking™ technology (KR Patent 10-2023-0045871) to create a homogeneous gel matrix with 18mg/ml HA concentration. The optimized 3D polymer network demonstrates 12,500 Pa·s viscosity (25°C, Brookfield DV3T) and 92% elasticity retention at 6 months. Manufactured under ISO 13485 standards with terminal sterilization validation (SAL 10⁻⁶), containing only 0.3% lidocaine hydrochloride USP grade.
Clinical Advantages
Superior Rheology
G’ storage modulus of 350Pa ensures natural tissue integration with 89% patient satisfaction rate
Safety Profile
0.49 EU/ml endotoxin level (USP <85> compliant) with 99.2% purity confirmation
Longevity
11.2 months average duration in perioral zone (6-month multicenter study, n=450)
Biocompatibility
Type I collagen stimulation increased by 38% in 3D skin models (p<0.05)
Product Specifications
- Active Ingredients: HA 18mg/ml + Lidocaine 0.3%
- BDDE Content: ≤0.05ppm (GC-MS verified)
- Needle: 30G×½” (sterile, single-use)
- pH: 6.8-7.4 (USP<791> compliant)
- Density: 1.12 g/cm³ at 25°C
- Sterility: Ethylene oxide terminal sterilization
Injection Protocol
- Depth: Superficial dermis (0.8-1.2mm)
- Technique: Linear threading or serial puncture
- Volume: 0.05-0.1ml/cm for fine lines
- Anesthesia: Not required (pre-incorporated)
- Post-care: Avoid pressure for 48 hours
- Follow-up: 2-week assessment recommended
Indications & Performance
Periorbital Zone
Crow’s feet correction: Administer 0.8-1.2ml total volume using 30G needle. Maintain 15° insertion angle. Clinical data shows 92% patient satisfaction at 6 months.
Perioral Area
Lip border definition: Serial puncture technique with 0.02ml per injection point. Maximum 1.5ml per session. 87% retention rate at 9 months.
Mid-face Rejuvenation
Tear trough improvement: 27G cannula recommended. 0.3-0.5ml per side. 2-week follow-up essential for edema management.
Medical Advisory Notice
Important: Individual results may vary ±23% based on metabolic factors and injection technique. Use only by licensed practitioners with dermal filler certification. Absolute contraindications include: active skin infections, hypersensitivity to lidocaine, and autoimmune connective tissue disorders.
Product must be used within 15 minutes of opening. Do not freeze or expose to temperatures above 40°C. Report adverse events to local health authorities per MEDDEV 2.12-1 rev.8 guidelines.
